245 related articles for article (PubMed ID: 18832878)
21. Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy.
Sparano JA; Hu X; Wiernik PH; Sarta C; Reddy DM; Hanau L; Henry DH
J Natl Cancer Inst; 1997 Feb; 89(4):301-7. PubMed ID: 9048834
[TBL] [Abstract][Full Text] [Related]
22. Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection.
Alejos B; Hernando V; Iribarren J; Gonzalez-García J; Hernando A; Santos J; Asensi V; Gomez-Berrocal A; Del Amo J; Jarrin I;
Medicine (Baltimore); 2016 Sep; 95(36):e4727. PubMed ID: 27603368
[TBL] [Abstract][Full Text] [Related]
23. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
Wannamethee SG; Sirivichayakul S; Phillips AN; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
Int J Epidemiol; 1998 Apr; 27(2):289-95. PubMed ID: 9602412
[TBL] [Abstract][Full Text] [Related]
24. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
25. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.
Bedimo RJ; McGinnis KA; Dunlap M; Rodriguez-Barradas MC; Justice AC
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):203-8. PubMed ID: 19617846
[TBL] [Abstract][Full Text] [Related]
26. Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital.
Mzileni MO; Longo-Mbenza B; Chephe TJ
Pol Arch Med Wewn; 2008 Oct; 118(10):548-54. PubMed ID: 19112815
[TBL] [Abstract][Full Text] [Related]
27. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.
Neilan AM; Karalius B; Patel K; Van Dyke RB; Abzug MJ; Agwu AL; Williams PL; Purswani M; Kacanek D; Oleske JM; Burchett SK; Wiznia A; Chernoff M; Seage GR; Ciaranello AL;
JAMA Pediatr; 2017 May; 171(5):450-460. PubMed ID: 28346597
[TBL] [Abstract][Full Text] [Related]
28. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
29. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States.
Melekhin VV; Shepherd BE; Jenkins CA; Stinnette SE; Rebeiro PF; Bebawy SS; Rasbach DA; Hulgan T; Sterling TR
AIDS Patient Care STDS; 2010 May; 24(5):279-86. PubMed ID: 20438375
[TBL] [Abstract][Full Text] [Related]
30. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort.
Pacheco YM; Jarrin I; Rosado I; Campins AA; Berenguer J; Iribarren JA; Rivero M; Muñoz-Medina L; Bernal-Morell E; Gutiérrez F; Leal M;
Antiviral Res; 2015 May; 117():69-74. PubMed ID: 25766861
[TBL] [Abstract][Full Text] [Related]
31. Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies.
Trickey A; May MT; Gill MJ; Grabar S; Vehreschild J; Wit FWNM; Bonnet F; Cavassini M; Abgrall S; Berenguer J; Wyen C; Reiss P; Grabmeier-Pfistershammer K; Guest JL; Shepherd L; Teira R; d'Arminio Monforte A; Del Amo J; Justice A; Costagliola D; Sterne JAC
Int J Cancer; 2020 Jun; 146(11):3134-3146. PubMed ID: 32003460
[TBL] [Abstract][Full Text] [Related]
32. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.
; Young J; Psichogiou M; Meyer L; Ayayi S; Grabar S; Raffi F; Reiss P; Gazzard B; Sharland M; Gutierrez F; Obel N; Kirk O; Miro JM; Furrer H; Castagna A; De Wit S; Muñoz J; Kjaer J; Grarup J; Chêne G; Bucher H
PLoS Med; 2012; 9(3):e1001194. PubMed ID: 22448150
[TBL] [Abstract][Full Text] [Related]
33. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
; Lundgren JD; Babiker A; El-Sadr W; Emery S; Grund B; Neaton JD; Neuhaus J; Phillips AN
J Infect Dis; 2008 Apr; 197(8):1145-55. PubMed ID: 18476293
[TBL] [Abstract][Full Text] [Related]
34. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa.
Lawn SD; Little F; Bekker LG; Kaplan R; Campbel E; Orrell C; Wood R
AIDS; 2009 Jan; 23(3):335-42. PubMed ID: 19114870
[TBL] [Abstract][Full Text] [Related]
35. CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).
Trickey A; May MT; Schommers P; Tate J; Ingle SM; Guest JL; Gill MJ; Zangerle R; Saag M; Reiss P; Monforte AD; Johnson M; Lima VD; Sterling TR; Cavassini M; Wittkop L; Costagliola D; Sterne JAC;
Clin Infect Dis; 2017 Sep; 65(6):959-966. PubMed ID: 28903507
[TBL] [Abstract][Full Text] [Related]
36. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.
Palella FJ; Baker RK; Moorman AC; Chmiel JS; Wood KC; Brooks JT; Holmberg SD;
J Acquir Immune Defic Syndr; 2006 Sep; 43(1):27-34. PubMed ID: 16878047
[TBL] [Abstract][Full Text] [Related]
37. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
[TBL] [Abstract][Full Text] [Related]
38. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
[TBL] [Abstract][Full Text] [Related]
39. Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy : A Multinational Prospective Cohort Study.
Chammartin F; Lodi S; Logan R; Ryom L; Mocroft A; Kirk O; d'Arminio Monforte A; Reiss P; Phillips A; El-Sadr W; Hatleberg CI; Pradier C; Bonnet F; Law M; De Wit S; Sabin C; Lundgren JD; Bucher HC;
Ann Intern Med; 2021 Jun; 174(6):768-776. PubMed ID: 33721519
[TBL] [Abstract][Full Text] [Related]
40. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy.
Kesselring A; Gras L; Smit C; van Twillert G; Verbon A; de Wolf F; Reiss P; Wit F
Clin Infect Dis; 2011 Jun; 52(12):1458-65. PubMed ID: 21628488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
